Professional Documents
Culture Documents
SJS Ten 1
SJS Ten 1
com
ISSN: 2277-3312 Journal DOI:10.7439/ijpr
Corresponding author*
Sriram Anne,
Hindu College of Pharmacy,
Amaravathi Road, Guntur-522006, India.
E-mail: anne.sriram@gmail.com
Abstract
Toxic epidermal necrolysis (TEN) and Stevens Johnson Syndrome (SJS) are severe adverse cutaneous drug
reactions that involve the skin and mucous membranes. They are characterized by mucocutaneous tenderness and
hemorrhagic erosions, erythema and more or less severe epidermal detachment presenting in areas of total skin. Drugs
are assumed or identified as the main cause of SJS/TEN in most cases, but Mycoplasma pneumoniae and Herpes simplex
virus infections are well documented causes rare cases in which the etiology remains unknown. Several drugs are at
"high" risk of inducing TEN/SJS including: Allopurinol, Trimethoprim-sulfamethoxazole and other sulfonamide-
antibiotics, aminopenicillins, cephalosporins, quinolones, carbamazepine, phenytoin, phenobarbital and NSAID.
Differential diagnosis includes IgA-dermatosis and paraneoplastic pemphigus, pemphigus vulgaris and bullous
pemphigoid, acute generalized exanthematous pustulosis (AGEP), disseminated fixed bullous drug eruption and
staphyloccocal scalded skin syndrome (SSSS). Due to the high risk of mortality, management of patients with SJS/TEN
requires rapid diagnosis, identification and interruption of the drugs, specialized supportive care ideally in an intensive
care unit, and provision of immunomodulating agents such as high-dose intravenous immunoglobulin therapy.
Keywords: Toxic epidermal necrolysis, Stevens Johnson Syndrome, skin and mucous membranes.
1. Introduction
Stevens-Johnson syndrome (SJS) is an immune-complexmediated hypersensitivity complex that typically
1
involves the skin and the mucous membranes . Stevens-Johnson syndrome was first described in 1922 as an extraordinary
and generalized epidermal eruption. It is accompanied by fever, inflammation of the buccal mucosa, and severe purulent
conjunctivitis. Incidence of this disorder is unknown, but it is thought to be very low. The etiology of this disorder is
multiple, including drugs, infectious agents, and idiopathic causes. The mortality rate mainly depends on the age and health
of the patient, and rates can range from 30 to 100 percent. Individuals with the very young or the old, are usually fatal
2-5
cases. Death is commonly due to infectious complications .
6,7
Toxic epidermal necrolysis (TEN) is usually drug-reaction . Drugs are an important cause of StevensJohnson
syndrome, but infections or a combination of infections and drugs has also been implicated. In case reports and studies,
8-13
more than 100 drugs have been implicated as causes of StevensJohnson syndrome or toxic epidermal necrolysis . A
limited number of drugs, including sulfonamides, anticonvulsant agents, and allopurinol, are the most consistently
associated with the conditions; whether nonsteroidal anti-inflammatory drugs (NSAIDs), analgesic agents, and
nonsulfonamide antibiotics are associated with them is controversial. The relative risk associated with the use of specific
drugs has never been quantified.
1
The simplest classification breaks the disease down as follows :
Stevens-Johnson syndrome: A minor form of toxic epidermal necrolysis, with less than 10% body surface area
(BSA) detachment
Overlapping Stevens-Johnson syndrome/toxic epidermal necrolysis: Detachment of 10-30% of the BSA.
Toxic epidermal necrolysis: Detachment of more than 30% of the BSA.
Both SJS and TEN are debatably included in the same spectrum as Erythema Multiforme (EM). This mucocutaneous
11,14
condition has similarities in clinical presentation to SJS/TEN but has some distinct differences as mentioned in table-1
and figure-1.
2. Etiology
Various etiologic factors have been implicated as causes of Stevens-Johnson syndrome. Drugs most commonly
are blamed. The 4 etiologic categories are as follows:
Infectious
Drug-induced
Malignancy-related
Idiopathic
2.1. Infectious causes
Viral diseases that have been reported to cause Stevens-Johnson syndrome include the following:
Herpes simplex virus (possibly; remains a debated issue)
AIDS
Coxsackie viral infections
Influenza
Hepatitis
Mumps
In children, Epstein-Barr virus and enteroviruses have been identified. More than half of the patients with
Stevens-Johnson syndrome report a recent upper respiratory tract infection.
Bacterial etiologies include the following:
Group A beta-hemolytic streptococci
Diphtheria
Brucellosis
Lymphogranuloma venereum
Mycobacteria
15,16
Mycoplasma pneumonia
Rickettsial infections
Tularemia
Typhoid
IJPR Volume 4 Issue 4 (2014) 159
Sriram Anne Review Article
2.2. Drug induced
Antibiotics are the most common cause of Stevens-Johnson syndrome, followed by analgesics, cough and cold
medication, NSAIDs, psychoepileptics, and antigout drugs. Of antibiotics, penicillins and sulfa drugs are prominent;
17
ciprofloxacin has also been reported .
The following anticonvulsants have been implicated:
Phenytoin
Carbamazepine
oxcarbazepine (Trileptal)
Valproic acid
Lamotrigine
Barbiturates
18
Belong to Mockenhapupt et al that most anticonvulsant-induced SJS occurs in the first 60 days of use .
19
Antiretroviral drugs implicated in Stevens-Johnson syndrome include nevirapine and possibly other non-nucleoside.
Stevens-Johnson syndrome has also been reported in patients taking the following drugs:
Modafinil (Provigil)
20
Allopurinol
21
Mirtazapine
22
TNF-alpha antagonists (eg, infliximab, etanercept, adalimumab)
Cocaine
Sertraline
Pantoprazole
Tramadol
2.3. Genetic factors:
Carriage of the following human leukocyte antigens has been associated with increased risk:
HLA-B*1502
HLA-B*5801
HLA-B*44
HLA-A29
HLA-B12
HLA-DR7
HLA-A2
HLA-B*5801
HLA-A*0206
HLA-DQB1*0601
Certain of these HLA alleles are associated with an increased probability of developing Stevens-Johnson
23
syndrome upon exposure to specific drugs. HLA-B*5801 confers a risk of allopurinol-related reactions. Pretreatment
24
screening is not readily available. HLA-A29, HLA-B12, and HLA-DR7 are frequently associated with sulfonamide-
induced Stevens-Johnson syndrome, while HLA-A2 and HLA-B12 are often encountered in Stevens-Johnson syndrome
induced by nonsteroidal anti-inflammatory drugs (NSAIDs). HLA-A*0206 and HLA-DQB1*0601 allele have been shown
25,26
to be was strongly associated with Stevens-Johnson syndrome with ocular disease. Nevertheless, whether the presence
of those genes constitutes a predisposition to Stevens-Johnson syndrome or whether those genes are in linkage
27
disequilibrium with more relevant adjacent genes is unknown.
4. Pathophysiology
The pathogenesis of SJS/TEN is not entirely based on the immune reaction, but also trusted with a implicating of
29,29
hypersensitivity reaction type III and IV .
Patients who are immunocompromised (especially those infected with HIV 30,31 ), and patients with brain tumors
has slow acetylators whose liver cannot completely detoxify reactive drug metabolites. These drug metabolites may have
32,33
direct toxic effects or may act as haptens that interact with host tissues, rendering them antigenic.
Both SJS and TEN are characterised by the detachment of epidermis from the papillary dermis at the epidermal-
36,37
dermal junction, manifesting as a papulomacular rash and bullae as a result of keratinocyte apoptosis . Keratinocyte
apoptosis mediated by cytotoxic T-lymphocytes (CD8) in SJS and TENS is modulated by plasma TNF-alpha and
38,39
interferon-gamma, which are increased in patients with SJS and TEN .
5. Diagnosis
The diagnosis relies on the one hand on clinical symptoms and on the other hand on histological features. Typical
clinical signs initially include areas of erythematous and macules on the skin, on which a positive Nikolsky sign can be
induced by mechanical pressure on the skin, followed within minutes to hours by the onset of epidermal detachment
characterized. To distinguish SJS, SJS-TEN and TEN the surface area of the detachment is the main discriminating factor.
Histological work up of immediate cryosections or conventional formalin-fixed sections of the skin revealing wide spread
necrotic epidermis involving all layers confirms the diagnosis.
5.1. Differential diagnosis
Major differential diagnosis of SJS/TEN are autoimmune diseases, including IgA-dermatosis and paraneoplastic
pemphigus but also pemphigus vulgaris and bullous pemphigoid, acute generalized exanthematous pustulosis (AGEP),
disseminated fixed bullous drug eruption and staphyloccocal scalded skin syndrome (SSSS). SSSS was one of the most
important differential diagnoses in the past, but the incidence is currently very low with 0.09 and 0.13 cases per one
45
million inhabitants per year .
References
1. French LE. Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. Allergol Int. Mar
2006; 55(1):9-16.
2. Huff JC, Weston WL, Tonnesen MG. Erythema multiforme: Critical review of characteristics, diagnostic criteria, and
causes. J Am Acad Dermatol 1983; 8:763-775.
3. Ackerman AB, Penneys NS, Clark WH. Erythema multiforme exudativum: Distinctive pathological process. Br J
Dermatol 1971; 84:554-566.
4. Yetiv JZ, Bianchine JR, Owen JA. Etiologic factors of the Stevens-Johnson syndrome. South Med J 1980; 73:599-602.
5. Bianchine JR, Macaraeg PV, Lasagn L, et al. Drugs as etiologic factors in the Stevens-Johnson syndrome. Am J Med
1968; 44:390-405.
6. Lyell A. Toxic epidermal necrolysis (the scalded skin syndrome): a reappraisal. Br J Dermatol 1979;100:69-86
7. Roujeau JC, Stern RS. Severe cutaneous adverse reactions to drugs. N Engl J Med1994; 331:1272-1285
8. Stern RS, Chan HL. Usefulness of case report literature in determining drugs responsible for toxic epidermal
necrolysis. J Am Acad Dermatol1989; 21:317-322.
9. Ruiz-Maldonado R. Acute disseminated epidermal necrosis types 1, 2, and 3: study of sixty cases. J Am Acad Dermatol
1985; 13:623-635.
10. Guillaume J-C, Roujeau J-C, Revuz J, Penso D, Touraine R. The culprit drugs in 87 cases of toxic epidermal necrolysis
(Lyell's syndrome). Arch Dermatol 1987; 123:1166-1170.
11. Roujeau J-C, Guillaume J-C, Fabre J-P, Penso D, Flechet ML, Girre JP. Toxic epidermal necrolysis (Lyell syndrome):
incidence and drug etiology in France, 1981-1985. Arch Dermatol1990; 126:37-42.
12. Schopf E, Stuhmer A, Rzany B, Victor N, Zentgraf R, Kapp JF. Toxic epidermal necrolysis and Stevens-Johnson
syndrome: an epidemiologic study from West Germany. Arch Dermatol 1991; 127:839-842.
13. Correia O, Chosidow O, Saiag P, Bastuji-Garin S, Revuz J, Roujeau J-C. Evolving pattern of drug-induced toxic
epidermal necrolysis. Dermatology 1993; 186:32-37.
14. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau J-C. Clinical classification of cases of toxic
epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129:92-96.
15. Hillebrand-Haverkort ME, Budding AE, bij de Vaate LA, van Agtmael MA. Mycoplasma pneumoniae infection with
incomplete Stevens-Johnson syndrome. Lancet Infect Dis. Oct 2008; 8(10):586-7.
16. Sendi P, Graber P, Lepre F, Schiller P, Zimmerli W. Mycoplasma pneumoniae infection complicated by severe
mucocutaneous lesions. Lancet Infect Dis. Apr 2008; 8(4):268.
17. Hllgren J, Tengvall-Linder M, Persson M, Wahlgren CF. Stevens-Johnson syndrome associated with ciprofloxacin: a
review of adverse cutaneous events reported in Sweden as associated with this drug. J Am Acad Dermatol. Nov 2003;
49(5 Suppl):S267-9.
18. Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal
necrolysis in new users of antiepileptics. Neurology. Apr 12 2005; 64(7):1134-8.
19. Metry DW, Lahart CJ, Farmer KL, Hebert AA. Stevens-Johnson syndrome caused by the antiretroviral drug nevirapine.
J Am Acad Dermatol. Feb 2001; 44(2 Suppl):354-7.
20. Halevy S, Ghislain PD, Mockenhaupt M, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome
and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. Jan 2008; 58(1):25-32.
21. Belkahia A, Hillaire-Buys D, Dereure O, Guillot B, Raison-Peyron N. Stevens-Johnson syndrome due to mirtazapine -
first case. Allergy. Oct 2009; 64(10):1554.
22. Salama M, Lawrance IC. Stevens-Johnson syndrome complicating adalimumab therapy in Crohn's disease. World J
Gastroenterol. Sep 21 2009; 15(35):4449-52.
23. Kardaun SH, Jonkman MF. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis.
Acta Derm Venereol. 2007; 87(2):144-8.
24. Fernando SL, Broadfoot AJ. Prevention of severe cutaneous adverse drug reactions: the emerging value of
pharmacogenetic screening. CMAJ. Mar 23 2010; 182(5):476-80.
25. Hynes AY, Kafkala C, Daoud YJ, Foster CS. Controversy in the use of high-dose systemic steroids in the acute care of
patients with Stevens-Johnson syndrome. Int Ophthalmol Clin. Fall 2005; 45(4):25-48.